Blockade of phosphodiesterase-III protects against oxygen-glucose deprivation in endothelial cells by upregulation of VE-cadherin

Current Neurovascular Research

Volumn 8, Issue 2, 2011, Pages 86-94

  Ishiguro, Mitsunori ^a,b   Suzuki, Yukiya ^a   Mishiro, Keisuke ^a   Kakino, Mamoru ^a   Tsuruma, Kazuhiro ^a   Shimazawa, Masamitsu ^a   Yoshimura, Shinichi ^b   Iwama, Toru ^b   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adheren junction; cAMP; Endothelial protection; Oxygen glucose deprivation; PDE III inhibitor; VE cadherin.

Indexed keywords

3'5' CYCLIC MONOPHOSPHATE SODIUM SALT; ACETYLSALICYLIC ACID; ADENOSINE 3',5' PHOSPHOROTHIOATE; ANGIOPOIETIN 1; CD31 ANTIGEN; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; GLUCOSE; LY 94002; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE III; RP CYCLIC ADENOSINE MONOPHOSPHOROTHIOATE; SODIUM; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CELL DAMAGE; CELL STRESS; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; OXYGEN GLUCOSE DEPRIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 79955709685     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720211795495385     Document Type: Article

References (29)

1. Tanaka K, Gotoh F, Fukuuchi Y, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989; 20: 668-73. (Pubitemid 19139099)
2. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6: 33-40. (Pubitemid 43261538)
3. Yoshimoto T, Shirasaka T, Fujimoto S, et al. Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2009; 49: 235-40.
4. Huang Y, Cheng Y, Wu J, et al. Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention Cooperation Investigators. Cilostazol asan alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-9.
5. Choi JM, Shin HK, Kim KY, et al. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002; 300: 787-93. (Pubitemid 34164980)
6. Nonaka Y, Koumura A, Hyakkoku K, et al. Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. J Pharmacol Exp Ther 2009; 330: 13-22.
7. Wakida K, Morimoto N, Shimazawa M, et al. Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res 2006; 1116: 187-93. (Pubitemid 44485011)
8. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300:709-715.
9. Dejana E. Endothelial cell-cell junctions: happy together. Nature Rev Mol Cell Biol 2004; 5: 261-70. (Pubitemid 38480607)
10. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147-57. (Pubitemid 29344903)
11. Blecharz KG, Drenckhahn D, Förster CY. Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J Cereb Blood Flow Metab 2008; 28: 1139-49. (Pubitemid 351733352)
12. Shinohara Y, Katayama Y, Uchiyama S, et al.; CSPS II group Cilostazol for prevention of secondary stroke (CSPS II): an aspirincontrolled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
13. Nonaka Y, Tsuruma K, Shimazawa M, et al. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett 2009; 452: 156-61.
14. Ishiguro M, Mishiro K, Fujiwara Y, et al. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010; 5: 12, e15178.
15. Ota H, Eto M, Kano MR, et al. Cilostazol inhibits oxidative stressinduced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 1634-39.
16. Hashimoto A, Miyakoda G, Hirose Y, et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006; 189: 350-7.
17. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84: 345-57. (Pubitemid 26058560)
18. Vittet D, Prandini MH, Berthier R, et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 1996; 88: 3424-31. (Pubitemid 26365576)
19. Herren B, Levkau B, Raines EW, et al. Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 1998; 9: 1589-601. (Pubitemid 28303499)
20. Nishino Y, Kashiwagi A, Takahara N, et al. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-α in vascular endothelial cells. Horm Metab Res 1997; 29: 491-5. (Pubitemid 27496343)
21. Torii H, Kubota H, Ishihara H, et al. Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res 2007; 55: 104-10. (Pubitemid 46186035)
22. Woodfin A, Voisin MB, Nourshargh S. PECAM-1, a multifunctional molecule in inflammation and vascular biology. Arterioscler. Thromb. Vasc. Biol 2007; 27: 2514-23. (Pubitemid 350158900)
23. Fukuhara S, Sakurai A, Yamagishi A, et al. Vascular endothelial cadherin-mediated cell-cell adhesion regulated by a small GTPase, Rap1. J. Biochem. Mol. Biol 2006; 39: 132-9.
24. Cullere X, Shaw SK, Andersson L, et al. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 2005; 105: 1950-5.
25. Lorenowicz MJ, Fernandez-Borja M, Kooistra MR, et al. PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. Eur. J. Cell Biol 2008; 87: 779-92.
26. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121: 2115-22.
27. Gavard J and Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8: 1223-34. (Pubitemid 44660587)
28. Augustin HG, Young KG, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
29. Lampugnani MG, Orsenigo F, Gagliani MC, et al. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006; 174:593-604. (Pubitemid 44231870)